CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...